Table 1.

Random effects linear model of HAM-D17 scores from 170 subjects refractory to Citalopram monotherapy who received either Bupropion or Venlafaxine as alternative treatments. The effects of Bupropion and Venlafaxine are measured with respect to observations obtained before administering these treatments.^a

Parameter name	Parameter estimate	P-value	95% CI
Fixed effects
Black raceb	3.54	0.001	[1.48, 5.59]
BUPc	−10.0	<0.001	[−11.3, −8.71]
VENd	−9.85	<0.001	[−10.9, −8.82]
Interaction Black race*BUP	5.24	0.002	[1.89, 8.58]
Intercept	17.0	<0.001	[16.1, 17.9]
Variances of random effects
BUP	10.6	--	[3.54, 31.8]
VEN	8.49	--	[2.77, 26.0]
Intercept	20.9	--	[14.9, 29.4]
Covariances between random effectse
Cov(BUP, Intercept)	−8.23	0.035	[−15.9, −0.59]
Cov(VEN, Intercept)	−8.06	0.022	[−15.0, −1.15]
Residual variance	19.9	--	[16.7, 23.6]

CI: Confidence interval; BUP: Bupropion; VEN: Venlafaxine.

^aBefore fitting the models, a few inconsistencies in the STAR*D data were found and corrected by the author. These inconsistencies and corrections were documented in a text file that is available from the author on request.

^bThe dichotomous variable was defined as 1 if the subject was self-declared black or African American, 0 otherwise.

^cThe dichotomous variable was defined as 1 if the HAM-D17 score was obtained under BUP treatment, or 0 if it was obtained at baseline or under VEN treatment.

^dThe dichotomous variable was defined as 1 if the HAM-D17 score was obtained under VEN treatment, or 0 if it was obtained at baseline or under BUP treatment.

^eSince subjects on BUP and VEN constituted two independent samples, the covariance between the random effects of BUP and VEN was fixed to 0 during parameter estimation.